Table 3.
Serum immunological characteristics of patients with BP according to mucosal involvement.
| All BP patients | Patients without mucosal involvement | Patients with mucosal involvement | Pvalue | |
|---|---|---|---|---|
| Serum anti-BP180 NC16A | ||||
| Number of patients (n)a | 94 | 76 | 18 | NA |
| Number of patients with titer ≥9 U/mL, n (%) | 77 (81.9) | 62 (81.6) | 15 (83.3) | 0.86 |
| Mean value ± SD (U/mL) | 63.9 ± 50.8 | 62 ± 50.1 | 71.9 ± 54.4 | 0.53 |
| Serum anti-BP230 | ||||
| Number of patients (n)b | 93 | 75 | 18 | NA |
| Number of patients with titer ≥9 U/mL, n (%) | 44 (47.3) | 39 (52) | 5 (27.8) | 0.06 |
| Mean value ± SD (U/mL) | 29.1 ± 37 | 32.2 ± 37.8 | 16.2 ± 30.9 | 0.07 |
Subsets of BP patients with or without mucosal involvement were compared and P-value was obtained using Chi2 tests for comparison between qualitative variables and nonparametric, Mann–Whitney tests for comparison between quantitative values.
aPatients for whom serum anti-BP180 ELISA values were available.
bPatients for whom serum anti-BP230 ELISA values were available.
NA, not applicable; BP, bullous pemphigoid; ELISA, enzyme-linked immunosorbent assay.